M Haroon A Choudry1, Yongli Shuai2, Heather L Jones3, Reetesh K Pai4, James F Pingpank3, Steven S Ahrendt3, Matthew P Holtzman3, Herbert J Zeh3, David L Bartlett3. 1. Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, PA, USA. choudrymh@upmc.edu. 2. The University of Pittsburgh Medical Cancer Hillman Cancer Center Biostatistics Facility, Pittsburgh, PA, USA. 3. Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
BACKGROUND: The authors hypothesized that postoperative complications after cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) have a negative impact on perioperative and oncologic outcomes and that the novel Comprehensive Comorbidity Index (CCI) would be a better predictor of such outcomes than the traditional Clavien-Dindo classification (CDC). METHODS: The study used a prospective database of 1296 patients with peritoneal metastases (PM) undergoing CRS-HIPEC between 2001 and 2016. The Kaplan-Meier method was used to estimate survival. Multivariate analyses identified associations with perioperative and oncologic outcomes. The Akaike information criterion and the Schwarz (Bayesian information) criterion were used to compare model fitting for CCI versus CDC. RESULTS: In this study, CRS-HIPEC was performed for malignant mesothelioma (12%) and PM from appendix (50%), colorectal (30%), and ovarian (8%) cancers. Major postoperative in-hospital complications (CDC grades 3-4) occurred for 24% of the patients. However, a range of CCI scores was calculated for each CDC grade because 36% of the patients experienced multiple complications. After a median follow-up period of 55 months, the median progression-free survival was 15 months, and the median overall survival was 39 months. In the multivariate Cox proportional hazards models, postoperative in-hospital complications (measured by CDC or CCI) were independent prognostic factors for 30-day post-discharge morbidity and readmission, as well as for survival. The CCI scores demonstrated higher prognostic sensitivity for these outcomes than CDC grades. CONCLUSIONS: Reduction of postoperative complications after CRS-HIPEC is essential for optimal short- and long-term outcomes. For assessing total burden of postoperative complications per patient, CCI is superior to CDC and more sensitive for assessing surgery- and cancer-related outcomes after CRS-HIPEC.
BACKGROUND: The authors hypothesized that postoperative complications after cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) have a negative impact on perioperative and oncologic outcomes and that the novel Comprehensive Comorbidity Index (CCI) would be a better predictor of such outcomes than the traditional Clavien-Dindo classification (CDC). METHODS: The study used a prospective database of 1296 patients with peritoneal metastases (PM) undergoing CRS-HIPEC between 2001 and 2016. The Kaplan-Meier method was used to estimate survival. Multivariate analyses identified associations with perioperative and oncologic outcomes. The Akaike information criterion and the Schwarz (Bayesian information) criterion were used to compare model fitting for CCI versus CDC. RESULTS: In this study, CRS-HIPEC was performed for malignant mesothelioma (12%) and PM from appendix (50%), colorectal (30%), and ovarian (8%) cancers. Major postoperative in-hospital complications (CDC grades 3-4) occurred for 24% of the patients. However, a range of CCI scores was calculated for each CDC grade because 36% of the patients experienced multiple complications. After a median follow-up period of 55 months, the median progression-free survival was 15 months, and the median overall survival was 39 months. In the multivariate Cox proportional hazards models, postoperative in-hospital complications (measured by CDC or CCI) were independent prognostic factors for 30-day post-discharge morbidity and readmission, as well as for survival. The CCI scores demonstrated higher prognostic sensitivity for these outcomes than CDC grades. CONCLUSIONS: Reduction of postoperative complications after CRS-HIPEC is essential for optimal short- and long-term outcomes. For assessing total burden of postoperative complications per patient, CCI is superior to CDC and more sensitive for assessing surgery- and cancer-related outcomes after CRS-HIPEC.
Authors: Caroline J Rieser; Jurgis Alvikas; Heather Phelos; Lauren B Hall; Amer H Zureikat; Andrew Lee; Melanie Ongchin; Matthew P Holtzman; James F Pingpank; David L Bartlett; M Haroon A Choudry Journal: Ann Surg Oncol Date: 2022-01-06 Impact factor: 5.344
Authors: Ashok K Dilly; Brendon D Honick; Robin Frederick; Anuleka Elapavaluru; Sachin Velankar; Hima Makala; T Kevin Hitchens; Lesley M Foley; Jianxia Guo; Jan H Beumer; Lora Heather Rigatti; Yong J Lee; David L Bartlett; Haroon A Choudry Journal: Transl Res Date: 2020-10-22 Impact factor: 7.012
Authors: Caroline J Rieser; Richard S Hoehn; Mazen Zenati; Lauren B Hall; Eliza Kang; Amer H Zureikat; Andrew Lee; Melanie Ongchin; Matthew P Holtzman; James F Pingpank; David L Bartlett; M Haroon A Choudry Journal: Ann Surg Oncol Date: 2021-03-09 Impact factor: 5.344
Authors: J Madison Hyer; Joal D Beane; Gaya Spolverato; Diamantis I Tsilimigras; Adrian Diaz; Alessandro Paro; Djhenne Dalmacy; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2021-09-10 Impact factor: 3.452
Authors: Caroline J Rieser; Lauren B Hall; Eliza Kang; Amer H Zureikat; Matthew P Holtzman; James F Pingpank; David L Bartlett; M Haroon A Choudry Journal: Ann Surg Oncol Date: 2021-01-23 Impact factor: 5.344
Authors: Michelle V Dietz; Job P van Kooten; Jeroen L A van Vugt; Alexandra R M Brandt-Kerkhof; Cornelis Verhoef; Eva V E Madsen Journal: Ann Surg Oncol Date: 2022-06-01 Impact factor: 4.339
Authors: Michelle V Dietz; Job P van Kooten; Ibrahim Said; Alexandra R M Brandt-Kerkhof; Cornelis Verhoef; Andreas J A Bremers; Johannes H W de Wilt; Philip R de Reuver; Eva V E Madsen Journal: Ann Surg Oncol Date: 2022-05-05 Impact factor: 4.339
Authors: Femke A van der Zant; Bob J L Kooijman; Judith E K R Hentzen; Wijnand Helfrich; Emily M Ploeg; Robert J van Ginkel; Barbara L van Leeuwen; Lukas B Been; Joost M Klaase; Patrick H J Hemmer; Christian S van der Hilst; Schelto Kruijff Journal: BJS Open Date: 2022-09-02
Authors: Caroline J Rieser; Heather Jones; Lauren B Hall; Eliza Kang; Shannon Altpeter; Amer H Zureikat; Matthew P Holtzman; Andrew Lee; Melanie Ongchin; James F Pingpank; M Haroon A Choudry; David L Bartlett Journal: Ann Surg Oncol Date: 2021-07-05 Impact factor: 5.344